(Boursier.com) — 2022, Theradiag generated revenue of €12.2 million compared to €11.1 million in 2021, an increase of +9.7%.
The operating result increased by +68.4% and stood at -278 KEUR, illustrating the improvement in the management of operating expenses and the increase in sales of products with higher margins.
Net income excluding exceptional items increased by +77.0% compared to the same period in 2021, from -679 KEUR to -156 KEUR. It is approaching equilibrium and represents -1.2% of the
turnover.
Exceptional expenses for the 2022 financial year amount to 331 KEUR and are mainly composed of costs related to the public tender offer operation of BioSynex and the accelerated amortization of R&D projects abandoned in the Covid. Overall, the net result increased by +36.5% and amounted to -487 KEUR.
As of December 31, 2022, Theradiag’s cash amounted to €6.4 million compared to €7.1 million as of December 31, 2021.
©2023 Boursier.com